1162262-35-2

Basic information

• Product Name: 2-(4-DifluoroMethoxy-3-fluorophenyl)-4,4,5,5-tetraMethyl -[1,3,2]dioxaborolane
• Synonyms: 2-(4-DifluoroMethoxy-3-fluorophenyl)-4,4,5,5-tetraMethyl -[1,3,2]dioxaborolane
• CAS NO: 1162262-35-2
• Molecular Formula: C₁₃H₁₆BF₃O₃
• Molecular Weight: 288.0705496
• Mol File: 1162262-35-2.mol
• Article Data: 8

Chemical Properties

• Boiling Point: 327.2±42.0 °C(Predicted)
• Appearance: /
• Density: 1.18±0.1 g/cm3(Predicted)
• CAS DataBase Reference: 2-(4-DifluoroMethoxy-3-fluorophenyl)-4,4,5,5-tetraMethyl -[1,3,2]dioxaborolane(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(4-DifluoroMethoxy-3-fluorophenyl)-4,4,5,5-tetraMethyl -[1,3,2]dioxaborolane(1162262-35-2)
• EPA Substance Registry System: 2-(4-DifluoroMethoxy-3-fluorophenyl)-4,4,5,5-tetraMethyl -[1,3,2]dioxaborolane(1162262-35-2)

Safety Data

• Hazardous Substances Data: 1162262-35-2(Hazardous Substances Data)

Usage

Uses

2-(4-Difluoromethoxy-3-fluoro-phenyl)-4,4,5,5-tetramethyl-[1,3,2]dioxaborolane (cas# 1162262-35-2) is used as a reagent in the preparation of imidazopyrazine derivatives as antibacterials.

Upstream product

• 147992-27-6 4-bromo-1-(difluoromethoxy)-2-fluoro-benzene 
• 73183-34-3 bis(pinacol)diborane 
• 2105-94-4 4-bromo-2-fluorophenol 

Downstream Products

• 1354289-42-1 5-(4-(difluoromethoxy)-3-fluorophenyl)-2-morpholinopyridin-4-amine 
• 1354287-56-1 1-(4-(5-(4-(difluoromethoxy)-3-fluorophenyl)-2-morpholinopyridin-4-ylamino)-5,7-difluoro-3-methylquinolin-2-yl)-4,4-dimethylpyrrolidin-2-one 
• 1354287-52-7 N-(5-(4-(difluoromethoxy)-3-fluorophenyl)-2-morpholinopyridin-4-yl)-5,7-difluoro-3-methyl-2-(pyridin-2-yl)quinolin-4-amine 

Relevant articles and documents

NOVEL IMIDAZO-PYRAZINE DERIVATIVES

The invention provides novel imidazo-pyrazine derivatives having the general formula (I), and pharmaceutically acceptable salts thereof, wherein X, m, n, and R1to R3 are as described herein: formula (I). Further provided are pharmace

Discovery of VU6005649, a CNS Penetrant mGlu7/8 Receptor PAM Derived from a Series of Pyrazolo[1,5-a]pyrimidines

Herein, we report the structure-activity relationships within a series of mGlu7 PAMs based on a pyrazolo[1,5-a]pyrimidine core with excellent CNS penetration (Kps > 1 and Kp,uus > 1). Analogues in this series proved to dis

HETEROCYCLIC COMPOUNDS AND THEIR USE AS INHIBITORS OF PI3K ACTIVITY

Substituted bicyclic heteroaryls and compositions containing them, for the treatment of general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, including but not restricted to autoimmune diseases such as systemic lupus erythematosis (SLE), myestenia gravis, rheumatoid arthritis, acute disseminated encephalomyelitis, idiopathic thrombocytopenic purpura, multiples sclerosis, Sjoegren's syndrome and autoimmune hemolytic anemia, allergic conditions including all forms of hypersensitivity, The present invention also enables methods for treating cancers that are mediated, dependent on or associated with p110 activity, including but not restricted to leukemias, such as Acute Myeloid leukaemia (AML) Myelo-dysplastic syndrome (MDS) myelo-proliferative diseases (MPD) Chronic Myeloid Leukemia (CML) T-cell Acute Lymphoblastic leukaemia ( T-ALL) B-cell Acute Lymphoblastic leukaemia (B-ALL) Non Hodgkins Lymphoma (NHL) B-cell lymphoma and solid tumors, such as breast cancer.